222 related articles for article (PubMed ID: 30345486)
1. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis.
Chinnaratha MA; Campbell K; Mathias R; McCormick RJ; Woodman RJ; Wigg AJ
J Gastrointest Cancer; 2019 Dec; 50(4):888-893. PubMed ID: 30345486
[TBL] [Abstract][Full Text] [Related]
2. The Improvement in 1-Year Survival Rate of Patients with Hepatocellular Carcinoma BCLC Stage A and B after the Implementation of Comprehensive Management.
Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
J Gastrointest Cancer; 2020 Sep; 51(3):829-835. PubMed ID: 31502104
[TBL] [Abstract][Full Text] [Related]
3. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.
De Toni EN; Schlesinger-Raab A; Fuchs M; Schepp W; Ehmer U; Geisler F; Ricke J; Paprottka P; Friess H; Werner J; Gerbes AL; Mayerle J; Engel J
Gut; 2020 Jan; 69(1):168-176. PubMed ID: 30878947
[TBL] [Abstract][Full Text] [Related]
4. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study.
Costentin CE; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Letouzé E; Imbeaud S; Zucman-Rossi J; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2018 Aug; 155(2):431-442.e10. PubMed ID: 29729258
[TBL] [Abstract][Full Text] [Related]
5. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening.
Tseng PL; Wang JH; Tung HD; Hung CH; Kee KM; Chen CH; Chang KC; Lee CM; Changchien CS; Chen PF; Tsai LS; Lu SN
J Gastroenterol Hepatol; 2010 Aug; 25(8):1426-34. PubMed ID: 20659234
[TBL] [Abstract][Full Text] [Related]
6. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
7. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.
Qian MY; Yuwei J R; Angus P; Schelleman T; Johnson L; Gow P
J Gastroenterol Hepatol; 2010 May; 25(5):951-6. PubMed ID: 20546449
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study.
Costentin CE; Mourad A; Lahmek P; Causse X; Pariente A; Hagège H; Dobrin AS; Becker C; Marks B; Bader R; Condat B; Héluwaert F; Seitz JF; Lesgourgues B; Denis J; Deuffic-Burban S; Rosa I; Decaens T;
Cancer; 2018 May; 124(9):1964-1972. PubMed ID: 29589878
[TBL] [Abstract][Full Text] [Related]
10. Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma.
Hester CA; Karbhari N; Rich NE; Augustine M; Mansour JC; Polanco PM; Porembka MR; Wang SC; Zeh HJ; Singal AG; Yopp AC
Cancer; 2019 Oct; 125(19):3428-3436. PubMed ID: 31299089
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
Kim NG; Nguyen PP; Dang H; Kumari R; Garcia G; Esquivel CO; Nguyen MH
Cancer; 2018 Jun; 124(12):2588-2598. PubMed ID: 29624631
[TBL] [Abstract][Full Text] [Related]
13. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?
Piñero F; Rubinstein F; Marciano S; Fernández N; Silva J; Zambelo Y; Anders M; Zerega A; Ridruejo E; Miguez C; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Rosales C; Romero G; McCormack L; Reggiardo V; Colombato L; Gadano A; Silva M
Dig Dis Sci; 2019 Mar; 64(3):718-728. PubMed ID: 30511199
[TBL] [Abstract][Full Text] [Related]
14. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
[TBL] [Abstract][Full Text] [Related]
15. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
16. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.
Moon AM; Weiss NS; Beste LA; Su F; Ho SB; Jin GY; Lowy E; Berry K; Ioannou GN
Gastroenterology; 2018 Oct; 155(4):1128-1139.e6. PubMed ID: 29981779
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.
Kim HD; Lim YS; Han S; An J; Kim GA; Kim SY; Lee SJ; Won HJ; Byun JH
Gastroenterology; 2015 Jun; 148(7):1371-82. PubMed ID: 25733098
[TBL] [Abstract][Full Text] [Related]
18. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
Liu W; Zheng Y; He W; Zou R; Qiu J; Shen J; Yang Z; Zhang Y; Wang C; Wang Y; Zuo D; Li B; Yuan Y
Aliment Pharmacol Ther; 2018 Sep; 48(6):671-681. PubMed ID: 30063081
[TBL] [Abstract][Full Text] [Related]
19. The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection.
Wang G; Zhang W; Tan Y; Jiang L; Yang J; Yang J; Yan L
Int J Surg; 2019 Dec; 72():1-6. PubMed ID: 31610283
[TBL] [Abstract][Full Text] [Related]
20. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
